Skip to content

Registry of Congenital Dyserythropoietic Anemia

French National Registry of Congenital Dyserythropoietic Anemia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03983629
Acronym
CDA
Enrollment
200
Registered
2019-06-12
Start date
2017-02-23
Completion date
2022-02-28
Last updated
2019-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Dyserythropoietic Anemia

Keywords

Congenital Dyserythropoietic Anemia, French registry

Brief summary

Congenital dyserythropoietic anemia is a heterogeneous inherited disease. Hyperplasic erythropoiesis is ineffective and associated with morphological abnormalities of some of the erythroblasts that form the basis of cytological classification. The cumulative incidence is not very clear, but varies between countries from 0.08 million in Scandinavia to 2.6 cases/million inhabitants in Italy where it appears to be the most reported. The common manifestation is moderate chronic congenital anemia. This anaemia is either normocytic or discreetly macrocytic, non-regenerative or inappropriate regarding anaemia, contrasting with signs of hemolysis with moderate unconjugated hyperbilirubinemia. Diagnosis is usually made in the pediatric period, but because of the great heterogeneity, the diagnosis sometimes may be delayed. Splenomegaly and jaundice are mostly present. Secondary hemochromatosis is common in the absence of transfusion due to hyper-intestinal absorption of iron induced by the dyserythropoiesis. The transmission mode for Type I and II is autosomal recessive, while it is autosomal dominant or sporadic for Type III. Several clinical questions remain concerning this disease : * the median survival of patients is not well known, neither the causes of death * benefit/risk of splenectomy * iron overload quantification and consequences The idea is to stablish a French registry of congenital dyserythropoietic anemia in order to help to understand the correlation between phenotype and genotype of this disease.

Interventions

OTHERCollection of data and genetic analysis

Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing

Sponsors

Lille Catholic University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patient with confirmed CDA * No opposition to the use of health data for research purposes

Exclusion criteria

* Patient opposed to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Percentage of mutationsup to three yearsGenetic analysis will be performed with whole genome and whole exome sequencing

Secondary

MeasureTime frame
Median survivalup to three years
Prevalence of different causes of deathup to three years
Rate of Interferon treatment efficacyup to three years

Countries

France

Contacts

Primary ContactAmélie Lansiaux, MD, PhD
lansiaux.amelie@ghicl.net320225269
Backup ContactJean-Jacques Vitagliano, PhD
vitagliano.jean-jacques@ghicl.net320225751

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026